ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Chervin AS, Stone JD, Konieczna I, Calabrese KM, Wang N, Haribhai D, Dong F, White MK, Rodriguez LE, Bukofzer GT, Ellis PA, Cosgrove C, Hecquet C, Clarin JD, Palma JP, Reilly EB.
Chervin AS, et al.
Mol Cancer Ther. 2023 Aug 1;22(8):903-912. doi: 10.1158/1535-7163.MCT-22-0770.
Mol Cancer Ther. 2023.
PMID: 37294945
Here we describe the generation and preclinical evaluation of ABBV-184, a novel TCR/anti-CD3 bispecific composed of a highly selective soluble TCR that binds a peptide derived from the oncogene survivin (BIRC5) bound to the class I MHC allele human leukocyte antigen (HLA)- …
Here we describe the generation and preclinical evaluation of ABBV-184, a novel TCR/anti-CD3 bispecific composed of a highly selective solub …